Cancer Research UK's Therapeutic Discovery Laboratories (CRUK-TDL), formerly CRT Discovery Laboratories, is the in-house CRUK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry.

Below you can find a list of all the current members of the Hannon lab at the CRUK-CI. Click on their names to find out more about their interests and projects. For a list of former members, please go to Alumni.

We specialise in imaging cancer, developing immune-targeted tools, and using single-cell technologies to study tumours. The immune system is intricately involved in all aspects of cancer. While many neoplastic cells are detected and eliminated by immune cells, inflammation is also a fundamental driver of tumourigenesis.

The Cancer Molecular Diagnostics Laboratory (CMDL) is part of the University of Cambridge School of Clinical Medicine Dept. of Oncology, located on the Cambridge Biomedical Campus. The laboratory is jointly funded by the Cancer Research UK Cambridge Centre and the NIHR Cambridge Biomedical Research Centre.

Ongoing work in the lab seeks to understand the role of metabolism more broadly in drug resistance and tumour progression. We are also expanding the reach of WILD-seq to diverse tumour types and model systems, including patient-derived cell and xenograft models, as well as adding new capabilities on top of lineage tracing and transcriptomics.

We study the genetic changes that happen in ovarian cancer to understand what causes cancer cells to become resistant to treatment. We use medical imaging technology to study how tumours respond to treatment and also to help us study cancers that have spread to …

We work on cellular stress response with particular emphasis on cellular senescence. Senescent cells are not just arrested cells. They are actively engaging in shaping local tissue or even the systemic environment. As a mechanism of such cellular activities, we focus on gene regulation through high-order chromatin organisation.

The Creixell lab integrates machine learning and high-throughput biochemistry to study how proteins selectively recognize their substrates, how this process is perturbed in cancer and how it can be hijacked to find highly selective and mutant-specific drugs to overcome drug resistance.

FGF receptor and ERK5 in particular have been implicated in prostate cancer. Work in our lab continues to explore the significance of these signalling pathways, to investigate tumour biology using in vitro and in vivo models and to develop specific small molecule inhibitors.

‪CRUK Cambridge Institute, University of Cambridge‬ - ‪‪Cited by 11,622‬‬ - ‪Circulating DNA - Molecular Diagnostics - Cancer Genomics - Biotechnology - NGS‬